SPRO - Spero Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.89
-0.17 (-1.88%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.06
Open9.14
Bid0.00 x 900
Ask0.00 x 800
Day's Range8.87 - 9.24
52 Week Range7.99 - 14.48
Volume68,575
Avg. Volume53,330
Market Cap170.049M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-2.61
Earnings DateMar 11, 2020 - Mar 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
  • Introducing Spero Therapeutics (NASDAQ:SPRO), A Stock That Climbed 11% In The Last Year
    Simply Wall St.

    Introducing Spero Therapeutics (NASDAQ:SPRO), A Stock That Climbed 11% In The Last Year

    Spero Therapeutics, Inc. (NASDAQ:SPRO) shareholders might be concerned after seeing the share price drop 19% in the...

  • GlobeNewswire

    Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced preliminary findings from its Phase 1 first-in-humans clinical trial of SPR206, an IV-administered product candidate being developed by Spero as an innovative option to treat MDR Gram-negative bacterial infections. Analysis of preliminary, blinded data from the Phase 1 double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial in healthy adult volunteers suggests that SPR206 is well-tolerated at doses that are likely to be within a therapeutic range for target MDR Gram-negative bacterial infections and has a safety profile that Spero believes supports the further development of SPR206.

  • Benzinga

    Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus

    Biotech stocks advanced in the penultimate week of the year, and the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) is on track to end the year with gains in excess of 25%. The previous week saw FDA ...

  • Here is What Hedge Funds Think About Spero Therapeutics, Inc. (SPRO)
    Insider Monkey

    Here is What Hedge Funds Think About Spero Therapeutics, Inc. (SPRO)

    Is Spero Therapeutics, Inc. (NASDAQ:SPRO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds have […]

  • Iterum Down as Sulopenem Antibiotic Fails in Phase III Study
    Zacks

    Iterum Down as Sulopenem Antibiotic Fails in Phase III Study

    Iterum's antibiotic candidate, sulopenem, fails to meet the primary endpoint of non-inferiority to Merck's Invanz in a late-stage study, evaluating it in complicated intra-abdominal infections.

  • Spero Posts Preliminary Data on SPR720 for Pulmonary Disease
    Zacks

    Spero Posts Preliminary Data on SPR720 for Pulmonary Disease

    Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.

  • GlobeNewswire

    Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced preliminary findings from a Phase 1 first-in-human clinical trial of SPR720, its oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Analysis of blinded data from the Phase 1 double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial in healthy volunteers suggests that SPR720 is generally well-tolerated, with a pharmacokinetic (PK) profile that Spero believes supports the further development of SPR720 as an oral agent for the treatment of NTM pulmonary disease.

  • GlobeNewswire

    Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Nov. 29, 2019 -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire

    Spero Therapeutics to Host Key Opinion Leader Symposium in December

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it will host a key opinion leader breakfast symposium on the unmet need, treatment landscape and potential for oral SPR994 as a new therapeutic option in complicated urinary tract infections (cUTI), as well as the opportunity for oral SPR720 in non-tuberculous mycobacterial (NTM) infections. A pivotal Phase 3 clinical trial of SPR994 for the treatment of cUTI entitled ADAPT-PO continues to enroll patients, and Spero expects to report top-line data from the Phase 3 clinical trial in the third quarter of 2020.

  • Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates

    Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -18.75% and 128.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review

    CAMBRIDGE, Mass., Nov. 04, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • How Many Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Do Institutions Own?
    Simply Wall St.

    How Many Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Do Institutions Own?

    If you want to know who really controls Spero Therapeutics, Inc. (NASDAQ:SPRO), then you'll have to look at the makeup...

  • GlobeNewswire

    Spero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial

    “The Phase 3 trial is designed to evaluate whether an oral-only regimen of SPR994 can achieve an outcome similar to that observed with an intravenous antibiotic therapy in patients with complicated urinary tract infections.   If SPR994 achieves this outcome and is ultimately approved, we believe it would represent a critical clinical and economic value proposition for the more than two million patients resistant to oral therapies currently used to treat such infections,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics.  “A primary objective of the independent review committee was to confirm that plasma levels of SPR994 in patients in the Phase 3 trial support the selected treatment dose consistent with our goals for the trial. The independent review committee reviewed interim plasma concentration data from 33 patients  who were randomized to SPR994 in the ongoing ADAPT-PO pivotal Phase 3 clinical trial for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).

  • GlobeNewswire

    Spero Therapeutics Announces Presentations at IDWeek 2019

    CAMBRIDGE, Mass., Sept. 26, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates

    Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -29.82% and -68.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update

    CAMBRIDGE, Mass., Aug. 08, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
    Zacks

    Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it has received a $5.9 million award from the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) Joint Warfighter Medical Research Program (Award number W81XWH-19-1-0295).  The U.S. Army Medical Research Acquisition Activity, 839 Chandler Street, Fort Detrick MD 21702- 5014 is the awarding and administering acquisition office. The funding will support the further clinical development of SPR206, Spero’s intravenous (IV)-administered product candidate from its Potentiator Platform that is being developed as an innovative alternative option to treat MDR Gram-negative bacterial infections.

  • Did Changing Sentiment Drive Spero Therapeutics's (NASDAQ:SPRO) Share Price Down By 15%?
    Simply Wall St.

    Did Changing Sentiment Drive Spero Therapeutics's (NASDAQ:SPRO) Share Price Down By 15%?

    It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

  • GlobeNewswire

    Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosis

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it entered into a collaboration with the Bill & Melinda Gates Medical Research Institute (Gates MRI) to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis (Mtb), an indication that is designated as a critical concern by the World Health Organization (WHO). SPR720 is an orally administered antimicrobial agent currently being developed by Spero Therapeutics for the treatment of rare non-tuberculous mycobacterial (NTM) infections.  Spero has granted Gates MRI an exclusive license to develop, manufacture and commercialize SPR720 for the treatment of tuberculosis (TB) in low- and middle- income countries (LMIC).  Gates MRI will conduct and fund preclinical and clinical studies for the development of SPR720 against TB, and also fund certain collaborative activities in furtherance of Gates MRI’s charitable purposes.  SPR720 was discovered by Vertex Pharmaceuticals and was acquired by Spero Therapeutics in 2016.

  • GlobeNewswire

    Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference

    CAMBRIDGE, Mass., June 17, 2019 -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and.

  • GlobeNewswire

    Spero Announces $10 Million Registered Direct Offering of Common Stock

    Spero Therapeutics, Inc. (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today announced that it has entered into a definitive agreement to sell up to $10,000,000 of Spero’s common stock in a registered direct offering with Novo Holdings A/S to be issued in two tranches.  The first tranche of the offering consists of 465,983 shares sold at a price of $10.73 per share, for aggregate gross proceeds to the Company of approximately $5,000,000, and is expected to close on or about June 14, 2019, subject to the satisfaction of customary closing conditions. The closing of the second tranche of $5,000,000 is triggered upon the earlier of (i) Spero’s public announcement of pharmacokinetic data from the lead-in cohort in its Phase 3 clinical trial of SPR994 and (ii) June 30, 2020.  The number of shares to be sold in the second tranche will be determined by the volume weighted average trading price (VWAP) of Spero’s common stock around the trigger date.